|
Cellectar Biosciences, Inc. (CLRB) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Cellectar Biosciences, Inc. (CLRB) Bundle
Designed for accuracy, our Cellectar Biosciences, Inc. (CLRB) DCF Calculator empowers you to evaluate Cellectar Biosciences' valuation using real-world financial data, offering complete flexibility to modify all essential parameters for improved projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -13.9 | -15.1 | -24.0 | -28.7 | -38.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .2 | .2 | .2 | .2 | .2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -14.1 | -15.4 | -24.2 | -28.9 | -39.0 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 10.6 | 57.2 | 35.7 | 19.9 | 9.6 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.3 | 1.4 | 1.4 | 2.6 | 5.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -.1 | -.1 | -.2 | -.9 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0.15771 | 0.15771 | 0.15771 | 0.15771 | 0.15771 | 0.15771 | 0.15771 | 0.15771 | 0.15771 | 0.15771 |
| EBITAT | -13.9 | -15.0 | -24.1 | -28.8 | -38.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -12.4 | -14.7 | -24.0 | -27.7 | -36.5 | -5.6 | .0 | .0 | .0 | .0 |
| WACC, % | 8.59 | 8.58 | 8.59 | 8.59 | 8.59 | 8.59 | 8.59 | 8.59 | 8.59 | 8.59 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -5 | |||||||||
| Net Debt | -9 | |||||||||
| Equity Value | 4 | |||||||||
| Diluted Shares Outstanding, MM | 12 | |||||||||
| Equity Value Per Share | 0.31 |
What You Will Get
- Pre-Filled Financial Model: Cellectar Biosciences' actual data allows for accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, margins, WACC, and other essential drivers.
- Instant Calculations: Automatic updates provide immediate results as you make adjustments.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation.
- Customizable and Reusable: Designed for flexibility, enabling repeated use for in-depth forecasts.
Key Features
- Customizable Research Parameters: Adjust essential factors such as clinical trial timelines, revenue projections, and R&D investments.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
- High-Precision Accuracy: Incorporates Cellectar Biosciences, Inc.'s (CLRB) actual financial data for credible valuation results.
- Effortless Scenario Analysis: Easily explore various hypotheses and assess different outcomes.
- Efficiency Booster: Avoid the complexities of developing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Cellectar Biosciences data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Cellectar Biosciences’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Cellectar Biosciences, Inc. (CLRB)?
- Designed for Experts: A sophisticated tool tailored for researchers, investors, and financial analysts.
- Current Market Data: Cellectar's historical and projected financial information preloaded for precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly Interface: Clear, step-by-step guidance to navigate through the calculations.
Who Should Use This Product?
- Investors: Accurately estimate Cellectar Biosciences, Inc.'s (CLRB) fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Cellectar Biosciences, Inc. (CLRB).
- Consultants: Quickly customize the template for valuation reports tailored to Cellectar Biosciences, Inc. (CLRB) clients.
- Entrepreneurs: Discover insights into financial modeling practices used by leading biotech firms like Cellectar Biosciences, Inc. (CLRB).
- Educators: Employ it as a teaching resource to illustrate valuation methodologies relevant to Cellectar Biosciences, Inc. (CLRB).
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Cellectar Biosciences, Inc. (CLRB).
- Real-World Data: Cellectar Biosciences’ historical and projected financials preloaded for analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to test various scenarios for Cellectar Biosciences, Inc. (CLRB).
- Financial Statements: Full annual and quarterly breakdowns for deeper insights into Cellectar Biosciences, Inc. (CLRB).
- Key Ratios: Built-in analysis for profitability, efficiency, and leverage specific to Cellectar Biosciences, Inc. (CLRB).
- Dashboard with Visual Outputs: Charts and tables for clear, actionable results regarding Cellectar Biosciences, Inc. (CLRB).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.